Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model – Starpharma
29 August 2019 Melbourne, Australia: Starpharma today announced that treatment with a novel HER-2 Targeted DEP® conjugate from its internal Targeted DEP® program resulted in tumour regression and 100% survival in a preclinical human ovarian cancer model. This finding builds on…
Next step in Alzheimer’s disease treatment – SVI & Janssen Pharmaceucticals Inc
29 August 2019 SVI has announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with focus on Alzheimer’s disease treatment. The objective of…
The Australian PBS approves Mayne Pharma’s Kapanol morphine drug for reimbursement
29 August 2019 Mayne Pharma says the Australian Pharmaceutical Benefits Scheme has approved its Kapanol morphine drug for palliative care chronic breathlessness for reimbursement. Mayne Pharma said that from September 1, 2019 eligible palliative care patients taking 10mg…
Efficacy signals have been observed in Starpharma’s clinical trials of dendrimer enhanced product (DEP) cabazitaxel and docetaxel
29 August 2019 Starpharma said both DEP-cabazitaxel and DEP-docetaxel had been showing “promising interim results”, with several patients dosed with DEP-cabazitaxel showing efficacy signals in tumors including prostate, ovarian and pancreatic cancer. In January 2018, Starpharma said it…
Bluechiip revenue for FY19 up 82.5%
29 August 2019 Bluechiip says revenue for the year to June 30, 2019 was up 82.5 percent to a record $1,025,052 with net loss after tax up 30.7 percent to $3,257,996. Bluechiip said revenue was from sales of…
Noxopharm’s NOX66 reduces tumor size and pain in patient study for prostate cancer
29 August 2019 Noxopharm says interim three-month results of its 11-patient study of Veyonda or NOX66 with radiotherapy for prostate cancer has reduced tumor size and pain. Noxopharm said it administered a single, 15-day course of 1,200mg of…
Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
27 August 2019 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production.…
Nucleus Network expansion creates first global, multi-site early phase trial organisation with investment in USA-based phase I clinical trials organization, Prism Clinical Research.
27 August, 2019 Nucleus Network, Australia’s leading early-phase clinical research organization, is pleased to announce it has acquired a majority shareholding in Prism Clinical Research, a 52-bed, early-phase clinical research facility located in Minneapolis/St. Paul, Minnesota, USA. The…
NOX receives 2018/19 Federal Government R&D tax rebate
23 August 2019 Sydney, Australia. Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Officer, said,…
Applications open for Victorian Government Women’s Board Leadership Program
26 August 2019 Nominations close: Tuesday 10 September 2019 What is the Women’s Board Leadership Program? The Women’s Board Leadership Program encourages women to serve, stay, and excel on community and government boards. The program offers a range of governance…
PLEXOVAL exosome wound healing human study starts – Exopharm Limited
26 August 2019 Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. This is an important step forward as a…
Research Australia welcome Australian Academic and Researcher to its Board of Directors
22 August 2019 Research Australia has welcomed to its Board, Professor Melissa Little, Theme Director of Cell Biology at the Murdoch Children’s Research Institute, Program Leader of Stem Cells Australia, Professor, Department of Pediatrics, and Honorary Professor, Anatomy…
